Endocrinology

Your daily dose of the clinical news you may have missed.

Michael Crotty, MD, an expert in obesity medicine, discusses GLP-1RAs in the context of weight loss, including the novel dual agonist survodutide.

Your daily dose of the clinical news you may have missed.

In children aged 10 to <18 with T2D inadequately controlled on standard of care treatment, tirzepatide reduced HbA1c by an average of 2.2% and reduced BMI as well.

EASD 2025. A new oral GLP-1 receptor agonist, orforglipron, shows promise for significant weight loss and improved cardiometabolic health in adults with obesity.

EASD 2025: After initiating treatment with semaglutide, the number of people who reported experiencing constant thoughts about food throughout the day declined by 46%.

EASD 2025: Findings from a subanalysis of the REDEFINE 1 phase 3 trial support Novo Nordisk's plan to advance cagrilintide into a dedicated clinical program this year.

Real-time continuous glucose monitoring significantly enhances glycemic control in gestational diabetes, reducing risks for large newborns compared to traditional methods.

EASD 2025: The risk of developing the 4 primary subtypes of T2D was increased by as much as 3-fold and was not dependent on duration of smoking behavior.

Your daily dose of the clinical news you may have missed.

Nor does receiving a diabetes diagnosis guarantee optimal management as just one-fifth of people treated for the disease reached glycemic control in 2023.

At ESC 2025, the STEER study showed semaglutide reduced risk of heart attack, stroke, or death by 57% vs tirzepatide in adults with obesity and cardiovascular disease, complementing prior trial data.

Your daily dose of the clinical news you may have missed.

This week’s podcast episode covers CRC screening, GLP-1 eligibility in youth, women’s heart health, FIT outreach, and ultraprocessed food risks.

Patients taking orforglipron achieved significant weight loss, hemoglobin A1c reduction, and cardiometabolic benefits in the phase 3 ATTAIN-2 study, supporting upcoming global regulatory submissions.

People with obesity may shun basic primary care for fear of shaming, lectures, inhospitable equipment, and simple lack of respect from clinicians, authors found.

The combination of the Dexcom Stelo glucose biosensor with an AI platform provides real-time data on how food, exercise, stress, and sleep affect the body.

GLP-1 use was associated with lower overall cancer risk, with the strongest associations observed for endometrial and ovarian cancers and meningioma.

Your daily dose of the clinical news you may have missed.

The FDA's ODD award is based on the positive findings from the phase 2 TouCAHn trial, which also support Crinetics' robust phase 3 pivotal clinical trial program for the novel agent.

A Cleveland Clinic trial revealed that AI-driven precision treatment significantly reduced HbA1c and body weight, often eliminating need for medications other than metformin.

GLP-1 use among adults with diabetes peaked among those aged 50 to 64 years, was highest among Hispanic adults, and was more likely among those taking other antihyperglycemic agents.

Your daily dose of the clinical news you may have missed.

The Advisory Panel laid out 4 priority actions for clinicians, policy makers, and industry.

Your daily dose of the clinical news you may have missed.